What is Hello Heart?
Founded in 2013, Hello Heart operates at the intersection of health tech and preventative medicine. The company provides a comprehensive digital platform that empowers users to monitor and manage blood pressure and heart health metrics in real-time. By leveraging artificial intelligence and behavioral science, the platform facilitates proactive health management, helping users identify potential risks before they escalate into acute medical events. Its seamless integration into existing employer benefits programs makes it a highly scalable solution for large organizations aiming to reduce healthcare costs while improving employee wellness outcomes. As a member of the American Heart Association's Innovators Network, Hello Heart maintains a high standard of clinical relevance and technological efficacy.
How much funding has Hello Heart raised?
Hello Heart has raised a total of $136M across 4 funding rounds:
Series A
$9M
Series B
$12M
Series C
$45M
Series D
$70M
Series A (2018): $9M with participation from BlueRun Ventures, Resolute Ventures, and Maven Ventures
Series B (2019): $12M led by Khosla Ventures and Blue Run Ventures
Series C (2021): $45M supported by Maven Ventures, BlueRun Ventures, Resolute.Vc, Khosla Ventures, and IVP
Series D (2022): $70M featuring Stripes
Key Investors in Hello Heart
Khosla Ventures
A prominent venture capital firm founded by Vinod Khosla that provides strategic advice and capital to breakthrough technology companies across the health, AI, and enterprise sectors.
IVP
A Menlo Park-based growth-stage venture capital firm that specializes in supporting high-growth technology companies through scale-up phases and eventual IPO or M&A exits.
Stripes
A growth equity firm that partners with market-defining software and consumer businesses, providing the operational expertise and capital necessary to scale effectively.
What's next for Hello Heart?
With this latest round of financing, Hello Heart is well-positioned to accelerate its market penetration and enhance its AI-driven diagnostic capabilities. The strategic focus will likely shift toward expanding its footprint within the enterprise benefits market, further integrating with major health management programs like those offered by CVS Health. By continuing to refine its personalized coaching algorithms, the company aims to deepen its impact on chronic disease management, ultimately reducing the long-term financial and physical burden of heart disease. Investors remain optimistic that this capital will enable the firm to maintain its competitive edge in the rapidly evolving digital therapeutics landscape.
See full Hello Heart company page
